Altimmune to present at upcoming investor conferences, discussing pemvidutide's development for serious liver diseases.
Quiver AI Summary
Altimmune, Inc. announced that its management will participate in two upcoming investor conferences to discuss its lead investigational drug, pemvidutide, which is aimed at treating serious liver diseases. The first is the Jefferies Global Healthcare Conference on June 4, 2026, and the second is the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. Both events will feature fireside chats, which can be accessed via webcast on Altimmune's website. Pemvidutide is a dual-action therapy that targets glucagon and GLP-1 receptors, and it is in development for conditions such as metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. Further information can be found on the company's website.
Potential Positives
- Participation in prominent investor conferences demonstrates Altimmune's commitment to engaging with investors and increasing visibility in the biopharmaceutical industry.
- The announcement highlights the progress of Altimmune's lead candidate, pemvidutide, which addresses significant health issues related to liver diseases, signaling potential for strong market demand.
- Webcast availability for the fireside chats enhances transparency and accessibility for investors, allowing them to stay informed about the company's developments and strategies.
Potential Negatives
- Management's participation in investor conferences may indicate a need to reassure stakeholders about the company's progress and viability amidst ongoing challenges in clinical development.
FAQ
What investor conferences will Altimmune participate in?
Altimmune will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference.
What is the focus of Altimmune's lead investigational therapy?
Altimmune's lead candidate, pemvidutide, targets serious liver diseases, specifically metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
When will Altimmune’s conference presentations take place?
The presentations are scheduled for June 4 and June 10, 2026, at 12:50 p.m. ET and 8:00 a.m. ET respectively.
How can I watch Altimmune's conference presentations?
A webcast of the fireside chats will be available on Altimmune’s website in the Events section.
Who should I contact for investor inquiries at Altimmune?
For investor inquiries, contact Luis Sanay, CFA, Vice President, Investor Relations at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALT Insider Trading Activity
$ALT insiders have traded $ALT stock on the open market 9 times in the past 6 months. Of those trades, 9 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ALT stock by insiders over the last 6 months:
- JEROME BENEDICT DURSO (President and CEO) has made 3 purchases buying 47,500 shares for an estimated $169,458 and 0 sales.
- JOHN GILL has made 2 purchases buying 21,700 shares for an estimated $82,599 and 0 sales.
- GREGORY L WEAVER (Chief Financial Officer) has made 2 purchases buying 15,000 shares for an estimated $49,199 and 0 sales.
- WAYNE PISANO purchased 5,000 shares for an estimated $20,410
- DIANE JORKASKY purchased 527 shares for an estimated $2,002
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ALT Hedge Fund Activity
We have seen 115 institutional investors add shares of $ALT stock to their portfolio, and 81 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 3,117,521 shares (+48.9%) to their portfolio in Q4 2025, for an estimated $11,254,250
- MARSHALL WACE, LLP added 3,095,124 shares (+335.4%) to their portfolio in Q1 2026, for an estimated $9,532,981
- BLACKROCK, INC. added 3,090,979 shares (+31.9%) to their portfolio in Q1 2026, for an estimated $9,520,215
- MILLENNIUM MANAGEMENT LLC added 3,050,808 shares (+1471.1%) to their portfolio in Q1 2026, for an estimated $9,396,488
- ALYESKA INVESTMENT GROUP, L.P. added 2,644,600 shares (+inf%) to their portfolio in Q1 2026, for an estimated $8,145,368
- STATE STREET CORP added 2,025,847 shares (+39.6%) to their portfolio in Q1 2026, for an estimated $6,239,608
- JANE STREET GROUP, LLC removed 1,783,950 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $5,494,566
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ALT Price Targets
Multiple analysts have issued price targets for $ALT recently. We have seen 3 analysts offer price targets for $ALT in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $20.0 on 05/18/2026
- Jonathan Wolleben from Citizens set a target price of $11.0 on 05/14/2026
- William Woods from B. Riley Securities set a target price of $13.0 on 03/06/2026
Full Release
GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:
-
2026 Jefferies Global Healthcare Conference
Thursday, June 4, 2026
Fireside chat at 12:50 p.m. ET
New York, NY
-
Goldman Sachs 47
th
Annual Global Healthcare Conference
Wednesday, June 10, 2026
Fireside chat at 8:00 a.m. ET
Miami Beach, FL
A webcast of the fireside chats will be available via the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit
www.altimmune.com
.
Follow @Altimmune, Inc. on
LinkedIn
Follow @AltimmuneInc on
X
Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
[email protected]
Media Contact:
Real Chemistry
[email protected]
